Literature DB >> 17046729

Decreased expression of the GABAA receptor in fragile X syndrome.

Charlotte D'Hulst1, Natalie De Geest, Simon P Reeve, Debby Van Dam, Peter P De Deyn, Bassem A Hassan, R Frank Kooy.   

Abstract

After our initial discovery of under expression of the GABA(A) receptor delta subunit in a genome wide screening for differentially expressed mRNAs in brain of fragile X mice, a validated model for fragile X mental retardation syndrome, we analyzed expression of the 17 remaining subunits of the GABA(A) receptor using real-time PCR. We confirmed nearly 50% under expression of the delta subunit and found a significant 35%-50% reduction in expression of 7 additional subunit mRNAs, namely alpha(1), alpha(3), and alpha(4), beta(1) and beta(2) and gamma(1) and gamma(2), in fragile X mice compared to wild-type littermates. In concordance with previous results, under expression was found in cortex, but not in cerebellum. Moreover, decreased expression of specific GABA(A) receptor subunits in fragile X syndrome seems to be an evolutionary conserved hallmark since in the fragile X fly (Drosophila melanogaster) model we also found almost 50% under expression of all 3 subunits which make up the invertebrate GABA receptor, namely Grd, Rdl and Lcch3. In addition, we demonstrated a direct correlation between the amount of dFmrp and the expression of the GABA receptor subunits Rdl and Grd. Our results add evidence to previous observations of an altered GABAergic system in fragile X syndrome. Because GABA(A) receptors are the major inhibitory receptors in brain, involved in anxiety, depression, insomnia, learning and memory and epilepsy, processes also disturbed in fragile X patients, the well described GABA(A) receptor pharmacology might open new powerful opportunities for treatment of the behavioral and epileptic phenotype associated with fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046729     DOI: 10.1016/j.brainres.2006.08.115

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  150 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

Review 2.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

Review 3.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 4.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Fragile X Syndrome FMRP Co-localizes with Regulatory Targets PSD-95, GABA Receptors, CaMKIIα, and mGluR5 at Fiber Cell Membranes in the Eye Lens.

Authors:  Peter H Frederikse; Anoop Nandanoor; Chinnaswamy Kasinathan
Journal:  Neurochem Res       Date:  2015-08-23       Impact factor: 3.996

Review 7.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

Review 8.  The attentive brain: insights from developmental cognitive neuroscience.

Authors:  Dima Amso; Gaia Scerif
Journal:  Nat Rev Neurosci       Date:  2015-10       Impact factor: 34.870

9.  Regulation of GABAA receptors by fragile X mental retardation protein.

Authors:  Baosong Liu; Lijun Li; Juan Chen; Zefen Wang; Zhiqiang Li; Qi Wan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

Review 10.  The translation of translational control by FMRP: therapeutic targets for FXS.

Authors:  Jennifer C Darnell; Eric Klann
Journal:  Nat Neurosci       Date:  2013-04-14       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.